Challenging Cases in NTM-LD: Treating Refractory MAC and Mitigating Adverse Events

Program Overview

In this 15-minute activity, an expert panel comprised of 2 pulmonologists and a pulmonology advanced practice provider discuss the management of 2 challenging cases of Mycobacterium avium complex (MAC) lung disease. The panel will provide privileged insights into strategies for controlling refractory MAC lung disease, highlighting their unique roles in the interprofessional management of treatment-related adverse events.

Credit Expired

Target Audience

This activity is intended for pulmonology and infectious disease clinicians who manage patients with nontuberculous mycobacterial lung disease (NTM-LD).

Educational Objectives

Upon completion of this activity, participants should be better able to:

Develop personalized treatment strategies for NTM-LD based on current data, guidelines, and best practices
Integrate the unique roles and responsibilities of the interprofessional care team members when managing NTM-LD

Activity Faculty

Julie V. Philley, MD

Executive Vice President, Health Affairs
University of Texas Health Science Center at Tyler
Tyler, TX

Charles L. Daley, MD

Chief, Division of Mycobacterial and Respiratory Infections
National Jewish Health
Professor, Medicine
National Jewish Health, the University of Colorado and Icahn School of Medicine at Mt. Sinai
Denver, CO

Tara Sadler, APRN, MSN, FNP-C

Advanced Practice Provider
Pulmonary Clinic
University of Texas at Tyler Health Science Center
Tyler, TX

Featured RMEI CE Activities – Earn CE Credit(s)

Challenging Cases in NTM-LD: Treating Refractory MAC and Mitigating Adverse Events

Program Overview

Target Audience

Educational Objectives

Activity Faculty

Julie V. Philley, MD

Charles L. Daley, MD

Tara Sadler, APRN, MSN, FNP-C

Advances in Precision Medicine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Care: A Care Team Forum®

Refining Management of CMV After Transplant: Exploiting Recent Advances to Alleviate Patient Burden

Overcoming Obstacles to Optimal Multiple Sclerosis (MS) Care in Minority Patient Populations

Subscribe